Headline Details

Spark's price for Luxturna blindness gene therapy too high: ICER

Published on: Fri, 12 Jan 2018 20:33:57 UTC
News Agency: Reuters
Description:
(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

Click here for FULL Story on Reuters

Also happening now

HeadlineNews Agency
Trump invites Putin to Washington despite U.S. uproar over Helsinki summit Reuters
Brazil's 'Dr. Butt' plastic surgeon arrested after patient death: police Reuters
Turkish court rejects Australia's request to extradite Islamic State recruiter Reuters
The transgender acid attack survivor running for parliament BBC
Were occult practices behind India's 'house of mass hangings'? BBC